Merck to acquire Caraway Therapeutics
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
The newly established business will be looking for high-quality, mid- to late-stage assets, clinically focused on the United States market
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
Sales in the US region grew well, partially offset by the decline in the LATAM and European regions
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
Lack of technology transfer stands out as a formidable barrier
The newly developed adhesive is available in two different grades. Loctite WT 3001 and Loctite WT 3003 h
Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026
Subscribe To Our Newsletter & Stay Updated